Biological E currently has a couple of in-house COVID-19 vaccines under development. Biological e vaccine name is not finalised yet. Biological E got a major manufacturing contract agreement for Johnson & Johnson’s single-dose COVID-19 vaccine.
Biological e vaccine maker Company details
Biological E is a biotech pioneer and currently makes eight World Health Organization (WHO) pre-qualified vaccines for tetanus, measles and rubella, pentavalent vaccines and snake anti-venom, and sells to over 100 countries. Biological E company was started by Dr DVK Raju and G.A.N. Raju in 1953 as India’s first biological products company manufacturing liver extracts and anti-coagulants.
Biological E COVID-19 vaccine wiki
Biological E licensed a recombinant protein COVID-19 vaccine candidate, developed by Houston-based health sciences university Baylor College of Medicine. Biological E is currently developing Covid single shot vaccine too. As per the details, Houston health sciences university transferred the technology to Biological E company for scaling up manufacturing and undertaking further development of the vaccine candidate.
Biological E company and the university entered into a deal for development of an affordable vaccine, especially for low- and middle-income nations.
Biological E has overall manufacturing capacity of over 1 billion doses per annum if required, when its vaccines are ready for production.
Biological E vaccine details
Biological E initiated phase I/II clinical trial of its COVID-19 subunit vaccine. The Biological E vaccine candidate included an antigen in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialization team, along with Dynavax’s advanced adjuvant CpG 1018, to boost the immune response to produce more antibodies and longer lasting immunity.
The Biological E COVID-19 vaccine candidate is based on classical vaccine technology of a protein antigen, SARS-CoV-2 spike protein, adsorbed to the adjuvant Alhydrogel (Alum), in combination with another approved adjuvant, CpG 1018.
as per the latest news from the media outlets, The COVID-19 vaccine of Biological–E is currently undergoing Phase-3 clinical trial after showing promising results in Phase 1 and 2. Government of India to pay Rs 1500 crore advance to procure 30 crore doses.